Zacks Research Has Negative Outlook for PCRX Q4 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Equities researchers at Zacks Research dropped their Q4 2026 earnings estimates for shares of Pacira BioSciences in a note issued to investors on Thursday, July 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.65 for the quarter, down from their previous forecast of $0.66. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.41 per share. Zacks Research also issued estimates for Pacira BioSciences' Q2 2027 earnings at $0.61 EPS.

PCRX has been the topic of a number of other research reports. Wall Street Zen raised shares of Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Finally, HC Wainwright lifted their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $26.44.

Pacira BioSciences Stock Down 1.9%

PCRX traded down $0.43 during trading on Monday, reaching $21.82. The company had a trading volume of 327,490 shares, compared to its average volume of 533,846. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.41 and a quick ratio of 1.99. Pacira BioSciences has a 12 month low of $11.16 and a 12 month high of $27.64. The business's fifty day moving average price is $24.34 and its 200 day moving average price is $24.46. The company has a market cap of $1.01 billion, a P/E ratio of -9.57 and a beta of 0.48.

Institutional Trading of Pacira BioSciences

A number of institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in shares of Pacira BioSciences by 0.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,992,601 shares of the company's stock worth $37,541,000 after purchasing an additional 13,604 shares in the last quarter. Doma Perpetual Capital Management LLC lifted its position in shares of Pacira BioSciences by 3.2% in the first quarter. Doma Perpetual Capital Management LLC now owns 1,804,069 shares of the company's stock worth $44,831,000 after purchasing an additional 56,220 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Pacira BioSciences in the first quarter worth $32,506,000. Goldman Sachs Group Inc. lifted its position in shares of Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock worth $27,454,000 after purchasing an additional 367,869 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Pacira BioSciences by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,091,970 shares of the company's stock worth $20,578,000 after purchasing an additional 5,071 shares in the last quarter. Institutional investors own 99.73% of the company's stock.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 5,578 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $26.21, for a total value of $146,199.38. Following the sale, the senior vice president owned 59,564 shares of the company's stock, valued at $1,561,172.44. The trade was a 8.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.40% of the stock is currently owned by corporate insiders.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.